Free Trial
NASDAQ:PPBT

Purple Biotech 11/21/2023 Earnings Report

Purple Biotech logo
$2.23 -0.02 (-0.89%)
Closing price 03:57 PM Eastern
Extended Trading
$2.23 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Purple Biotech EPS Results

Actual EPS
-$4.60
Consensus EPS
-$4.60
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Purple Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Purple Biotech Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Purple Biotech's next earnings date is estimated for Friday, August 15, 2025, based on past reporting schedules.

Conference Call Resources

Purple Biotech Earnings Headlines

Purple Biotech (PPBT) to Release Quarterly Earnings on Friday
Purple Biotech (NASDAQ:PPBT) Shares Down 4.9% After Earnings Miss
Trump’s AI Agenda: The 9 stocks poised to benefit most
While many are busy chasing the usual AI trends, a bigger opportunity is quietly brewing—and most are missing it. Imagine a major shift in how and where AI is built, opening up incredible wealth opportunities for those in the know. I’ve found 9 AI companies primed to lead this change. These aren’t the tired “AI hype” stocks; they’re companies with real US operations, proven revenue growth, and deep AI integration.
See More Purple Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Purple Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Purple Biotech and other key companies, straight to your email.

About Purple Biotech

Purple Biotech (NASDAQ:PPBT) Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

View Purple Biotech Profile

More Earnings Resources from MarketBeat